<?xml version="1.0" encoding="UTF-8"?>

<PlanDefinition xmlns="http://hl7.org/fhir">
  <id value="RecCollectionTherapeuticAnticoagNonICUHighRiskCOVID19Patients"/>
  <meta>
    <profile value="https://www.netzwerk-universitaetsmedizin.de/fhir/cpg-on-ebm-on-fhir/StructureDefinition/recommendation"/>
  </meta>
  <text>
    <status value="generated"/><div xmlns="http://www.w3.org/1999/xhtml"><p class="res-header-id"><b>Generated Narrative: PlanDefinition RecCollectionTherapeuticAnticoagNonICUHighRiskCOVID19Patients</b></p><a name="RecCollectionTherapeuticAnticoagNonICUHighRiskCOVID19Patients"> </a><a name="hcRecCollectionTherapeuticAnticoagNonICUHighRiskCOVID19Patients"> </a><a name="RecCollectionTherapeuticAnticoagNonICUHighRiskCOVID19Patients-en-US"> </a><p><b>url</b>: <a href="PlanDefinition-RecCollectionTherapeuticAnticoagNonICUHighRiskCOVID19Patients.html">PlanDefinition Therapeutic anticoagulation in non-intensive care, high-risk COVID-19 patients</a></p><p><b>version</b>: 1.0</p><p><b>name</b>: 17 - Therapeutic Anticoagulation</p><p><b>title</b>: Therapeutic anticoagulation in non-intensive care, high-risk COVID-19 patients</p><p><b>type</b>: <span title="Codes:{http://terminology.hl7.org/CodeSystem/plan-definition-type workflow-definition}">Workflow Definition</span></p><p><b>status</b>: Active</p><p><b>experimental</b>: true</p><p><b>date</b>: 2022-02-14</p><p><b>publisher</b>: Deutsche Gesellschaft für Internistische Intensivmedizin und Notfallmedizin e.V. (DGIIN)</p><p><b>description</b>: </p><div><p>Bei hospitalisierten, nichtintensivpflichtigen Patienten mit COVID-19 und erhöhtem Risiko (z.B. D-Dimere ≥ 2 mg/l) kann bei niedrigem Blutungsrisiko eine therapeutische Antikoagulation, präferenziell mit NMH oder UFH, erwogen werden.</p>
</div><h3>Actions</h3><table class="grid"><tr><td style="display: none">-</td><td><b>Title</b></td><td><b>Description</b></td><td><b>Code</b></td><td><b>Definition[x]</b></td></tr><tr><td style="display: none">*</td><td>Therapeutic_Anticoagulation_No_Renal_Function_Impairment</td><td><div><p>Therapeutic Anticoagulation Plan (hospitalised, non-intensive care, COVID-19 patients)</p>
</div></td><td><span title="Codes:{http://hl7.org/fhir/uv/cpg/CodeSystem/cpg-common-process guideline-based-care}">Guideline-based Care</span></td><td><a href="PlanDefinition-TherapeuticAnticoagulationNonICUHighRiskCOVID19PatientsPlan.html">Therapeutic Anticoagulation Plan (hospitalised, non-intensive care, COVID-19 patients</a></td></tr></table></div>
  </text>
  <extension url="http://hl7.org/fhir/uv/cpg/StructureDefinition/cpg-knowledgeCapability">
    <valueCode value="computable"/>
  </extension>
  <extension url="http://hl7.org/fhir/uv/cpg/StructureDefinition/cpg-knowledgeRepresentationLevel">
    <valueCode value="structured"/>
  </extension>
  <extension url="https://www.netzwerk-universitaetsmedizin.de/fhir/cpg-on-ebm-on-fhir/StructureDefinition/ext-action-combination-method">
    <extension url="method">
      <valueCodeableConcept>
        <coding>
          <system value="https://www.netzwerk-universitaetsmedizin.de/fhir/cpg-on-ebm-on-fhir/CodeSystem/cs-action-combination-method"/>
          <code value="exactly"/>
        </coding>
      </valueCodeableConcept>
    </extension>
    <extension url="threshold">
      <valuePositiveInt value="1"/>
    </extension>
  </extension>
  <url value="https://www.netzwerk-universitaetsmedizin.de/fhir/codex-celida/guideline/covid19-inpatient-therapy/recommendation/therapeutic-anticoagulation"/>
  <version value="1.0"/>
  <name value="17 - Therapeutic Anticoagulation"/>
  <title value="Therapeutic anticoagulation in non-intensive care, high-risk COVID-19 patients"/>
  <type>
    <coding>
      <system value="http://terminology.hl7.org/CodeSystem/plan-definition-type"/>
      <code value="workflow-definition"/>
    </coding>
  </type>
  <status value="active"/>
  <experimental value="true"/>
  <date value="2022-02-14"/>
  <publisher value="Deutsche Gesellschaft für Internistische Intensivmedizin und Notfallmedizin e.V. (DGIIN)"/>
  <description value="Bei hospitalisierten, nichtintensivpflichtigen Patienten mit COVID-19 und erhöhtem Risiko (z.B. D-Dimere ≥ 2 mg/l) kann bei niedrigem Blutungsrisiko eine therapeutische Antikoagulation, präferenziell mit NMH oder UFH, erwogen werden."/>
  <action>
    <title value="Therapeutic_Anticoagulation_No_Renal_Function_Impairment"/>
    <description value="Therapeutic Anticoagulation Plan (hospitalised, non-intensive care, COVID-19 patients)"/>
    <code>
      <coding>
        <system value="http://hl7.org/fhir/uv/cpg/CodeSystem/cpg-common-process"/>
        <code value="guideline-based-care"/>
      </coding>
    </code>
    <definitionCanonical value="https://www.netzwerk-universitaetsmedizin.de/fhir/codex-celida/guideline/covid19-inpatient-therapy/intervention-plan/therapeutic-anticoagulation"/>
  </action>
</PlanDefinition>